Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315629547> ?p ?o ?g. }
- W4315629547 endingPage "401" @default.
- W4315629547 startingPage "393" @default.
- W4315629547 abstract "Evidence-practice gaps exist in urology. We previously surveyed European Association of Urology (EAU) guidelines for strong recommendations underpinned by high-certainty evidence that impact patient experience for which practice variations were suspected. The recommendation “Do not offer neoadjuvant androgen deprivation therapy (ADT) before surgery for patients with prostate cancer” was prioritised for further investigation. ADT before surgery is neither clinically effective nor cost effective and has serious side effects. The first step in improving implementation problems is to understand their extent. A clear picture of practice regarding ADT before surgery across Europe is not available. To assess current ADT use before prostate cancer surgery in Europe. This was an observational cross-sectional study. We retrospectively audited recent ADT practices in a multicentre international setting. We used nonprobability purposive sampling, aiming for breadth in terms of low- versus high-volume, academic, versus community and public versus private centres. Our primary outcome was adherence to the ADT recommendation. Descriptive statistics and a multilevel model were used to investigate differences between countries across different factors (volume, centre type, and funding type). Subgroup analyses were performed for patients with low, intermediate, and high risk, and for those with locally advanced prostate cancer. We also collected reasons for nonadherence. We included 6598 patients with prostate cancer from 187 hospitals in 31 countries from January 1, 2017 to May 1, 2020. Overall, nonadherence was 2%, (range 0–32%). Most of the variability was found in the high-risk subgroup, for which nonadherence was 4% (range 0–43%). Reasons for nonadherence included attempts to improve oncological outcomes or preoperative tumour parameters; attempts to control the cancer because of long waiting lists; and patient preference (changing one’s mind from radiotherapy to surgery after neoadjuvant ADT had commenced or feeling that the side effects were intolerable). Although we purposively sampled for variety within countries (public/private, academic/community, high/low-volume), a selection bias toward centres with awareness of guidelines is possible, so adherence rates may be overestimated. EAU guidelines recommend against ADT use before prostate cancer surgery, yet some guideline-discordant ADT use remains at the cost of patient experience and an additional payer and provider burden. Strategies towards discontinuation of inappropriate preoperative ADT use should be pursued. Androgen deprivation therapy (ADT) is sometimes used in men with prostate cancer who will not benefit from it. ADT causes side effects such as weight gain and emotional changes and increases the risk of cardiovascular disease, diabetes, and osteoporosis. Guidelines strongly recommend that men opting for surgery should not receive ADT, but it is unclear how well the guidance is followed. We asked urologists across Europe how patients in their institutions were treated over the past few years. Most do not use ADT before surgery, but this still happens in some places. More research is needed to help doctors to stop using ADT in patients who will not benefit from it." @default.
- W4315629547 created "2023-01-12" @default.
- W4315629547 creator A5000288345 @default.
- W4315629547 creator A5000680967 @default.
- W4315629547 creator A5000692088 @default.
- W4315629547 creator A5000772034 @default.
- W4315629547 creator A5000991854 @default.
- W4315629547 creator A5001217715 @default.
- W4315629547 creator A5001340494 @default.
- W4315629547 creator A5001342709 @default.
- W4315629547 creator A5001601149 @default.
- W4315629547 creator A5001608084 @default.
- W4315629547 creator A5001649397 @default.
- W4315629547 creator A5002985141 @default.
- W4315629547 creator A5002988049 @default.
- W4315629547 creator A5003694149 @default.
- W4315629547 creator A5004155775 @default.
- W4315629547 creator A5004173282 @default.
- W4315629547 creator A5004437594 @default.
- W4315629547 creator A5005075508 @default.
- W4315629547 creator A5005242331 @default.
- W4315629547 creator A5005883646 @default.
- W4315629547 creator A5006746754 @default.
- W4315629547 creator A5007005415 @default.
- W4315629547 creator A5007743887 @default.
- W4315629547 creator A5008596744 @default.
- W4315629547 creator A5008776276 @default.
- W4315629547 creator A5008896771 @default.
- W4315629547 creator A5008929412 @default.
- W4315629547 creator A5009829610 @default.
- W4315629547 creator A5010404240 @default.
- W4315629547 creator A5010483763 @default.
- W4315629547 creator A5010832454 @default.
- W4315629547 creator A5010924872 @default.
- W4315629547 creator A5011038720 @default.
- W4315629547 creator A5011520592 @default.
- W4315629547 creator A5012173280 @default.
- W4315629547 creator A5012375339 @default.
- W4315629547 creator A5013471317 @default.
- W4315629547 creator A5013839598 @default.
- W4315629547 creator A5013888713 @default.
- W4315629547 creator A5014278672 @default.
- W4315629547 creator A5015384107 @default.
- W4315629547 creator A5017892303 @default.
- W4315629547 creator A5018034940 @default.
- W4315629547 creator A5018282716 @default.
- W4315629547 creator A5018808876 @default.
- W4315629547 creator A5018822694 @default.
- W4315629547 creator A5019083341 @default.
- W4315629547 creator A5019298885 @default.
- W4315629547 creator A5019301288 @default.
- W4315629547 creator A5019498765 @default.
- W4315629547 creator A5020366463 @default.
- W4315629547 creator A5020529503 @default.
- W4315629547 creator A5020878795 @default.
- W4315629547 creator A5021151785 @default.
- W4315629547 creator A5021199527 @default.
- W4315629547 creator A5022322719 @default.
- W4315629547 creator A5022728935 @default.
- W4315629547 creator A5023265851 @default.
- W4315629547 creator A5023296374 @default.
- W4315629547 creator A5023354391 @default.
- W4315629547 creator A5023558049 @default.
- W4315629547 creator A5023640905 @default.
- W4315629547 creator A5023957347 @default.
- W4315629547 creator A5024927727 @default.
- W4315629547 creator A5025400909 @default.
- W4315629547 creator A5025571278 @default.
- W4315629547 creator A5025609533 @default.
- W4315629547 creator A5026028064 @default.
- W4315629547 creator A5026514560 @default.
- W4315629547 creator A5026938205 @default.
- W4315629547 creator A5028011301 @default.
- W4315629547 creator A5028312473 @default.
- W4315629547 creator A5028322367 @default.
- W4315629547 creator A5028466359 @default.
- W4315629547 creator A5028516510 @default.
- W4315629547 creator A5028592148 @default.
- W4315629547 creator A5028740085 @default.
- W4315629547 creator A5029776947 @default.
- W4315629547 creator A5030105260 @default.
- W4315629547 creator A5030554721 @default.
- W4315629547 creator A5030558226 @default.
- W4315629547 creator A5030563674 @default.
- W4315629547 creator A5030598536 @default.
- W4315629547 creator A5031087263 @default.
- W4315629547 creator A5031550729 @default.
- W4315629547 creator A5032156511 @default.
- W4315629547 creator A5032401545 @default.
- W4315629547 creator A5032406457 @default.
- W4315629547 creator A5032538862 @default.
- W4315629547 creator A5033054923 @default.
- W4315629547 creator A5034639999 @default.
- W4315629547 creator A5034646726 @default.
- W4315629547 creator A5034916507 @default.
- W4315629547 creator A5035088133 @default.
- W4315629547 creator A5035302506 @default.
- W4315629547 creator A5035617871 @default.